This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
by Zacks Equity Research
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns
by Zacks Equity Research
Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.
J&J (JNJ) to Explore Omicron Version of its COVID Vaccine
by Zacks Equity Research
J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?
by Zacks Equity Research
Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.
ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus
by Sanghamitra Saha
The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Cyber Monday to Determine Holiday Sales Fate
by Zacks Equity Research
Cyber Monday to Determine Holiday Sales Fate
Will Cyber Monday Rescue Holiday Shopping from Omicron Fears?
by Mark Vickery
Pre-market futures this morning are buoyant, indicating market participants may have overreacted to the Friday news.
Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
by Zacks Equity Research
Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
by Zacks Equity Research
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
Wall Street Tumbles on Resurgence of Coronavirus
by Zacks Equity Research
Wall Street Tumbles on Resurgence of Coronavirus.
Black Friday Meets "Black Friday:" New Covid Variant Hits Markets
by Mark Vickery
A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids
by Kinjel Shah
FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.
J&J (JNJ) Gets First Full Approval for COVID Jab in Canada
by Zacks Equity Research
Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.
Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year
by Zacks Equity Research
Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.
FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults
by Zacks Equity Research
The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.
Stock Market News for Nov 22, 2021
by Zacks Equity Research
Wall Street closed mixed on Friday to end a choppy week.
FDA Gives Authorization to Two COVID-19 Boosters
by Zacks Equity Research
FDA Gives Authorization to Two COVID-19 Boosters
FDA Authorizes Covid Boosters; New Fed Chair Soon?
by Mark Vickery
Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.
by Zacks Equity Research
The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.
Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill
by Kinjel Shah
J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.